Spinal cord lesions are frequently asymptomatic in relapsing–remitting multiple sclerosis: a retrospective MRI survey
Spinal cord (SC) involvement correlates with poor prognosis in patients with multiple sclerosis (MS). Nevertheless, there is no consensus on the use of SC-MRI at follow-up, mainly because of the belief that SC lesions are nearly always symptomatic.
The aim of the present study was to investigate the frequency of asymptomatic SC combined unique activity (CUA, new/enlarging T2 or gadolinium-positive [Gd+] lesions) on MRI in a cohort of patients diagnosed with clinically isolated syndrome (CIS) or relapsing–remitting MS (RRMS).
We retrospectively investigated all scans showing SC-CUA in patients with CIS or RRMS referred to a single Italian MS centre. We determined whether they were symptomatic and whether they had associated brain radiological activity.
In 340 SC-MRI scans with SC-CUA (230 patients), SC-CUA was asymptomatic in 31.2%; 12.1% of SC-CUA had neither clinical activity nor brain radiological activity (44.5% and 25.4%, respectively, considering only follow-up SC-CUA). At multivariate analysis asymptomatic SC-CUAs were associated with older age at onset (34.0 ± 10.37 vs 31.0 ± 9.99 years, p = 0.006), non-spinal onset (76.4 vs 47.4%, p < 0.001), lower EDSS score at MRI (1.8 ± 0.93 vs 2.4 ± 1.28, p = 0.001) and lower number of Gd+ SC lesions (0.1 ± 0.33 vs 0.3 ± 0.54, p = 0.04), compared to symptomatic SC-CUAs.
A substantial proportion of our patients had SC-CUA without clinical symptoms and/or without concomitant brain MRI activity. In these patients, SC-CUA was the only sign of disease activity, suggesting that regular SC-MRI follow-up is required for reliable assessment of radiological activity and may improve the management of patients with MS.
KeywordsMultiple sclerosis Spinal cord Asymptomatic MRI Follow-up
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Compliance with ethical standards
Conflicts of interest
F. Granella has received research grants for his Institution from Biogen and Sanofi Genzyme; has served on scientific advisory boards for Biogen, Novartis, Sanofi Genzyme, Roche and Merck Serono; and has received funding for travel from Biogen, Merck Serono and Sanofi Genzyme. E. Tsantes served on scientific advisory boards for Roche and Merck & Co; has received funding for travel from Biogen, Merck & Co, Sanofi Genzyme and Roche V. Bazzurri has received funding for travel from Sanofi Genzyme, Biogen and Roche. E. Curti served on scientific advisory boards for Merck & Co and Novartis; has received funding for travel from Biogen, Merck & Co, Teva Pharmaceutical Industries, Sanofi Genzyme, Roche and Novartis. S. Graziuso and G. Crisi have nothing to disclose.
- 10.Wattjes MP, Rovira À, Miller D et al (2015) Evidence based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—establishing disease prognosis and monitoring patients. Nat Rev Neurol 11:597–606Google Scholar
- 15.Ruggieri S, Logoteta A, Tinelli E et al (2018) Measuring disease activity in multiple sclerosis: the essential role of spinal cord MRI monitoring. ECTRIMS Online Library. Ruggieri S 2018; 228465 (P621)Google Scholar
- 20.Eckstein C, Syc S, Saidha S (2011) Differential diagnosis of longitudinally extensive transverse myelitis in adults. Eur Neurol J 3:27–39Google Scholar